Formulating Weakly Basic HCl Salts: Relative Ability of Common Excipients to Induce Disproportionation and the Unique Deleterious Effects of Magnesium Stearate
- 1.3k Downloads
Nine common excipients were examined to determine their ability to cause disproportionation of the HCl salt of a a weakly basic compound. The goal was to determine which excipients were problematic and correlate the results to known properties such as surface pH, slurry pH, or molecular structure. Such a correlation enables a general, simple excipient selection process.
Binary compacts and “pseudo formulations” are studied after stressing at 40°C/75%RH and 40°C/35% RH for up to 28 days. Near-Infrared (NIR) and X-Ray powder diffraction (XRPD) measurements monitored the conversion of the HCl salt to the free base.
The excipients which induced measureable disproportionation were magnesium stearate, sodium croscarmellose, and sodium stearyl fumarate. Magnesium stearate induced the most extensive and rapid disproportionation at 40°C/75%RH and 40°C/35%RH. Samples containing magnesium stearate showed a unique and significant water uptake above 31%RH.
The problematic excipients are best explained by the proton accepting capacity of excipient carboxylate groups which have pKa’s higher than the pHmax of the drug salt. Alternative lubricants and disintegrants are suggested and a simple excipient screening process is proposed. Magnesium stearate was the most deleterious excipient for HCl salts due to the formation of the deliquescent salt magnesium chloride.
Key wordsdeliquescent disproportionation excipient induced HCl salt Magnesium stearate
Acknowledgments and Disclosures
The authors would like to thank Dr. Patrick Marsac for performing the solid-state NMR analysis of compound A samples.
- 1.Lipinski CA. Poor aqueous solubility - An industry wide problem in drug discovery. Am Pharm Rev. 2002;5:82–5.Google Scholar
- 4.Keck CM, Kobierski S, Mauludin R, Müller RH. Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartcrystals technology. Dosis. 2008;24:124–8.Google Scholar
- 5.Timpe C. Strategies for formulation development of poorly water soluble candidates - a recent perspective. Am Pharm Rev. 2007;10(3):104–9.Google Scholar
- 7.Hageman M. Solubility, solubilization and dissolution in drug delivery during lead optimization. In: Borchardt R, editor. Optimizing the “Drug Like” properties of leads in drug discovery, biotechnology: Pharmaceutical aspects, vol. IV. New York: Springer; 2006. p. 100–30.Google Scholar
- 14.Maurin MB, Grant DJW, Stahl PH. The physicochemical background: Fundamentals of ionic equilibria. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: Properties, selection, and use. New York: Wiley-VCH; 2002. p. 9–18.Google Scholar
- 21.Adeyeye M. C. and Brittain H.G. (eds.). Preformulation in Solid Dosage Form Development, Informa Healthcare, 2008.Google Scholar
- 25.Glombitza BW, Oelkrug D, Schmidt PC. Surface acidity of solid pharmaceutical excipients I. Determination of the surface acidity. Eur J Pharm Biopharm. 1994;40:289–93.Google Scholar
- 28.Swaminathan V., Kildsig O., An Examination of the moisture sorption characteristics of Commercial Magnesium Stearate. AAPS PharmSciTech. 2001; 2(4) article 28.Google Scholar
- 34.Rahaman A, Grassian VH, Margulis CJ. Dynamics of water adsorption onto a calcite surface as a function of relative humidity. J Phys Chem. 2008;112:2109–15.Google Scholar